1 completed, 1 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Influenza B: new trials by email Literature Review of Influenza B trials Research Report on Influenza B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose, Safety, and Pathogenicity of a New Influenza B Strain influenza B/Connecticut/1/21 virus part a dose arm 1, influenza B/Connecticut/1/21 virus part a dose arm 2, influenza B/Connecticut/1/21 virus part b dose 1 - Influenza B | Phase 2 | Unknown | Hvivo | 60 | 2023-10-03 | 2024-02-12 |
| Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza Anti-Influenza Immune Plasma, Standard Care - Influenza A, Influenza B | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 98 | 2010-12-01 | 2017-09-05 |
Communicable Diseases, Emerging (1) · Influenza, Human (1) · Orthomyxoviridae Infections (1)
Infections (2) · RNA Virus Infections (2) · Virus Diseases (2) · Communicable Diseases (1) · Disease Attributes (1) · Orthomyxoviridae Infections (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1)
Standard of Care (1)
Hvivo (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United Kingdom (1) · United States (1)
John Beigel, MD (1) · Richard Davey, MD (1) · Victoria Parker, MBBS (1)